In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more
 

EHJ – Cardiovascular Pharmacotherapy

Specific Focus on Clinical Cardiovascular Pharmacology

 

The European Heart Journal – Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal reports on the interpretation and integration of new scientific developments  to improve the pharmacological treatment of patients with cardiovascular disease.

It publishes original articles on clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

Access your online journal

 

Fast Facts

  • Editor-in-chief: Stefan Agewall FESC, NO
  • Current volume: 6 (year 2020)
  • Issues per subscription: 4
  • Impact Factor 2019: 6.696

 

Editor in chief History

Name Start Date End Date
 Professor Stefan Agewall 01/01/2015  

Subscriptions

Subscribe

Connect with us on Twitter

@ESC_Journals
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

Sign up

For Authors

Before being published, all manuscripts go through double-blind, peer review by experienced international experts.

Submit a Manuscript

Submit

Instructions for Authors

Find out more

Publisher Information

See more

Frequently-Asked Questions

See more

Most recent articles from EHJ-CVP

13 May 2020
Focus on subpopulations of atrial fibrillation patients
Author(s):Agewall S.
01 Apr 2020
Speculation is not evidence: antihypertensive therapy and COVID-19
Author(s):de Simone G, Mancusi C.
13 Apr 2020
Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
Author(s):Acanfora D, Ciccone M, Scicchitano P, et al.
14 Jan 2020
Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations
Author(s):Rubboli A, Lip G.

 

 
About the ESC
Press and Media
Information
Follow us

         

 Contact us

© 2020 European Society of Cardiology. All rights reserved.